 Meredith Tennis
Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 19 | 2024 | 2353 | 2.830 |
Why?
| | Iloprost | 8 | 2023 | 46 | 2.610 |
Why?
| | Frizzled Receptors | 4 | 2022 | 23 | 1.730 |
Why?
| | Epoprostenol | 5 | 2021 | 135 | 1.680 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2024 | 1060 | 1.450 |
Why?
| | Smoke | 4 | 2020 | 142 | 1.120 |
Why?
| | Urethane | 4 | 2023 | 41 | 1.030 |
Why?
| | Wnt Proteins | 4 | 2012 | 127 | 1.020 |
Why?
| | MicroRNAs | 2 | 2022 | 671 | 0.820 |
Why?
| | Cigarette Smoking | 1 | 2022 | 90 | 0.690 |
Why?
| | Precancerous Conditions | 4 | 2024 | 164 | 0.690 |
Why?
| | Receptors, G-Protein-Coupled | 3 | 2010 | 199 | 0.660 |
Why?
| | PPAR gamma | 4 | 2022 | 182 | 0.620 |
Why?
| | Chemoprevention | 3 | 2023 | 88 | 0.590 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2022 | 191 | 0.580 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2010 | 322 | 0.580 |
Why?
| | Anticarcinogenic Agents | 1 | 2018 | 76 | 0.580 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2021 | 420 | 0.500 |
Why?
| | Epithelial Cells | 5 | 2022 | 1060 | 0.420 |
Why?
| | Nerve Tissue Proteins | 2 | 2021 | 568 | 0.400 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 31 | 0.390 |
Why?
| | Carcinogens | 3 | 2022 | 109 | 0.380 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2022 | 627 | 0.370 |
Why?
| | Antihypertensive Agents | 2 | 2017 | 487 | 0.360 |
Why?
| | Mice | 10 | 2023 | 16585 | 0.350 |
Why?
| | Cell Migration Inhibition | 1 | 2010 | 16 | 0.350 |
Why?
| | Growth Inhibitors | 1 | 2010 | 43 | 0.350 |
Why?
| | Signal Transduction | 5 | 2010 | 4863 | 0.330 |
Why?
| | Neoplasms, Second Primary | 1 | 2009 | 108 | 0.300 |
Why?
| | Glycoproteins | 1 | 2010 | 340 | 0.290 |
Why?
| | Adenocarcinoma | 2 | 2017 | 895 | 0.290 |
Why?
| | Bronchi | 3 | 2018 | 253 | 0.280 |
Why?
| | Lung | 7 | 2023 | 3928 | 0.280 |
Why?
| | Neoplasms, Experimental | 2 | 2018 | 168 | 0.280 |
Why?
| | DNA Methylation | 1 | 2012 | 601 | 0.270 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2522 | 0.270 |
Why?
| | Smoking | 2 | 2012 | 1507 | 0.270 |
Why?
| | Animals | 11 | 2023 | 34733 | 0.260 |
Why?
| | Cell Movement | 1 | 2010 | 934 | 0.250 |
Why?
| | Breast Neoplasms | 3 | 2021 | 2112 | 0.250 |
Why?
| | Mice, Transgenic | 3 | 2018 | 2075 | 0.220 |
Why?
| | Cell Line, Tumor | 4 | 2022 | 3106 | 0.210 |
Why?
| | Registries | 2 | 2009 | 2008 | 0.190 |
Why?
| | Disease Models, Animal | 2 | 2022 | 4016 | 0.190 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 53 | 0.180 |
Why?
| | Carmustine | 1 | 2020 | 50 | 0.180 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2021 | 80 | 0.180 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 154 | 0.180 |
Why?
| | Protein Domains | 1 | 2022 | 244 | 0.180 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 184 | 0.170 |
Why?
| | Carcinogenesis | 1 | 2021 | 200 | 0.170 |
Why?
| | Respiratory System | 1 | 2020 | 153 | 0.160 |
Why?
| | Cell Line | 2 | 2018 | 2768 | 0.160 |
Why?
| | Enzyme Inhibitors | 1 | 2022 | 828 | 0.160 |
Why?
| | Tobacco Smoking | 1 | 2018 | 26 | 0.150 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2018 | 67 | 0.150 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2018 | 131 | 0.140 |
Why?
| | Tobacco Smoke Pollution | 1 | 2020 | 233 | 0.140 |
Why?
| | Protein Binding | 1 | 2022 | 2088 | 0.130 |
Why?
| | Humans | 16 | 2024 | 129705 | 0.120 |
Why?
| | Cells, Cultured | 2 | 2021 | 4058 | 0.100 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2012 | 15 | 0.100 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1700 | 0.090 |
Why?
| | Cell Proliferation | 3 | 2018 | 2340 | 0.090 |
Why?
| | Desmoglein 3 | 2 | 2022 | 17 | 0.090 |
Why?
| | Azacitidine | 1 | 2012 | 138 | 0.090 |
Why?
| | Thyroid Nuclear Factor 1 | 1 | 2009 | 15 | 0.080 |
Why?
| | Luciferases | 1 | 2010 | 148 | 0.080 |
Why?
| | Mesoderm | 1 | 2010 | 139 | 0.080 |
Why?
| | RNA, Messenger | 2 | 2022 | 2705 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 479 | 0.080 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 132 | 0.080 |
Why?
| | Tumor Cells, Cultured | 1 | 2010 | 929 | 0.070 |
Why?
| | Tumor Suppressor Proteins | 1 | 2010 | 314 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 962 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2009 | 325 | 0.070 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1195 | 0.070 |
Why?
| | Inflammation | 1 | 2018 | 2705 | 0.070 |
Why?
| | Blotting, Western | 1 | 2010 | 1189 | 0.070 |
Why?
| | Biomarkers | 1 | 2018 | 3893 | 0.070 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 610 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2018 | 10299 | 0.070 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2005 | 71 | 0.060 |
Why?
| | Nuclear Proteins | 1 | 2009 | 644 | 0.060 |
Why?
| | Disease Progression | 2 | 2024 | 2612 | 0.060 |
Why?
| | Phenotype | 1 | 2012 | 3063 | 0.050 |
Why?
| | Formaldehyde | 1 | 2022 | 57 | 0.050 |
Why?
| | Keratin-5 | 1 | 2022 | 49 | 0.050 |
Why?
| | Algorithms | 1 | 2009 | 1632 | 0.050 |
Why?
| | Tubulin | 1 | 2022 | 131 | 0.050 |
Why?
| | Transcription Factors | 1 | 2009 | 1636 | 0.050 |
Why?
| | Female | 7 | 2022 | 68561 | 0.050 |
Why?
| | Lung Diseases | 1 | 2008 | 757 | 0.050 |
Why?
| | Prognosis | 1 | 2009 | 3801 | 0.050 |
Why?
| | Mice, Inbred A | 1 | 2020 | 49 | 0.040 |
Why?
| | Immunoblotting | 1 | 2021 | 303 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 763 | 0.040 |
Why?
| | gamma Catenin | 1 | 2018 | 14 | 0.040 |
Why?
| | Metaplasia | 1 | 2018 | 54 | 0.040 |
Why?
| | Bronchial Diseases | 1 | 2018 | 39 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2018 | 95 | 0.040 |
Why?
| | Receptors, Prostaglandin | 1 | 2017 | 22 | 0.040 |
Why?
| | Aged | 3 | 2018 | 22113 | 0.040 |
Why?
| | Biological Availability | 1 | 2017 | 129 | 0.040 |
Why?
| | Receptors, CXCR4 | 1 | 2017 | 82 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 173 | 0.030 |
Why?
| | Hydrogels | 1 | 2023 | 634 | 0.030 |
Why?
| | Middle Aged | 3 | 2018 | 31103 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 636 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1098 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 577 | 0.030 |
Why?
| | Macrophages | 1 | 2020 | 1459 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1315 | 0.020 |
Why?
| | United States | 1 | 2024 | 14078 | 0.020 |
Why?
| | Drug Design | 1 | 2008 | 157 | 0.020 |
Why?
| | Cobalt Radioisotopes | 1 | 2005 | 7 | 0.020 |
Why?
| | Cocarcinogenesis | 1 | 2005 | 14 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2005 | 75 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2005 | 249 | 0.020 |
Why?
| | Radiotherapy | 1 | 2005 | 186 | 0.010 |
Why?
| | Odds Ratio | 1 | 2005 | 1025 | 0.010 |
Why?
| | Adult | 1 | 2018 | 35595 | 0.010 |
Why?
| | Time Factors | 1 | 2005 | 6593 | 0.010 |
Why?
| | Male | 1 | 2018 | 63544 | 0.010 |
Why?
| | Risk Factors | 1 | 2005 | 9832 | 0.010 |
Why?
|
|
Tennis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|